Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=44 Resveratrol for Pain Due to Endometriosis
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
N/A N=56 Dyspareunia and Central Sensitization
Endometriosis · Central Sensitisation · Dyspareunia
Primary: Deep Dyspareunia Score — 3.08 scores on a scale
N/A N=35 Endometriosis Group Care
Endometriosis · Pelvic Pain
Primary: PROMIS Pain Interference SF 8a — -1.62 t-score
Phase 2 N=22 Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
Endometriosis-related Pain
Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale
N/A N=109 An AHEI Dietary Intervention to Reduce Pain in Women With Endometriosis
Endometriosis
Primary: Pain Measurement - Acyclic Pain — 7.1; 7.0; 4.7; 6.7 VAS pain score — p=0.02
Phase 3 N=872 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 19.6; 46.4; 75.8 percentage of participants — p=< 0.001
Phase 3 N=504 Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
Phase 2 N=10 Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
Endometriosis
Primary: Change in Score in Worst Pain Over the Last Month — -0.5; -5 score on a scale
Phase 2 N=30 Botulinum Toxin for Pelvic Pain in Women With Endometriosis
Endometriosis · Chronic Pelvic Pain · Pelvic Muscle Spasm
Primary: Number of Participants With Improvement in Pain — 11; 4 Participants
Phase 2 N=137 Efficacy and Safety Study of Elagolix in Women With Endometriosis
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase — -0.24; -0.49; -0.37; -1.13 units on a scale — p=0.0262
Phase 4 N=353 Chronic Pain Risk Associated With Menstrual Period Pain
Cystitis, Interstitial · Dysmenorrhea · Migraine Disorders
Primary: Change in Participant Bladder Pain Sensitivity From Baseline. — 38.2; 37.0; 41.2; 47.9 score on a scale — p=.02
Phase 2 N=60 Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Endometriosis · Ovarian Hyperstimulation
Primary: Average Delta in Endometriosis Pain Score Pre and Post Stimulation With and Without Use Of Letrozole — -2.5; -2.7 Change in score on a scale
Phase 3 N=681 A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment — 23.7; 62.8; 29.1; 63.8 percentage…
N/A N=167 A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laparoscopy to Detect Endometriosis
Endometriosis
Primary: Diagnostic Yield — 81; 25 participants
Phase 2 N=142 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Endometriosis
Primary: Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change) — -27.35; -34.72; -41.57; -18.61 percentage of change…
Phase 3 N=815 A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Endometriosis
Primary: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS) — 22.7; 43.4; 72.4 percentage of participants — p=< 0.001
Phase 2 N=328 A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Endometriosis
Primary: Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS) — 34.5; 49.4; 61.5; 56.4 percentage of subjects
Phase 2 N=76 Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
N/A N=19 Effects of Intravenous Lidocaine on Endometriosis Pain
Endometriosis
Primary: Change in Visual Analogue Scale (VAS) — -2.6; -0.2; -3.5; -1.5 units on a scale
N/A N=56 Enriched Environments in Endometriosis
Endometriosis-related Pain · Endometriosis · Pelvic Pain
Primary: Pain Perception — 7.0; 6.2; 7.2; 5.1 units on a scale
Phase 2 N=187 A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
Endometriosis-related Pain
Primary: Change From Baseline in Average Daily Pelvic Pain Score During Treatment Cycle 2 — -2.2; -1.7 Scores on a Scale — p=0.066
N/A N=52 Music for Pain in Primary Dysmenorrhea
Pain, Menstrual · Primary Dysmenorrhea
Primary: Change in Pain From 1-5 Minutes Before (Baseline) to 1- 5 Minutes After the Intervention — -1.85; -0.18 cm — p=0.002
N/A N=84 Decreasing Postoperative Pain Following Endometrial Ablation
Postoperative Pain
Primary: Postoperative Pain Score — 2.71; 1.44; 3.37; 2.81 units on a scale
Phase 2 N=8 Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Endometriosis
Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317
Phase 2 N=354 A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Endometriosis
Primary: Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3 — -1.8; -1.6; -1.5; -2.0 score on a scale
Phase 3 N=149 Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 2.4 units on a scale
Phase 3 N=495 Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 37.0; 57.1; 50.8; 75.9 percentage of participants
Phase 2 N=95 A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
Dysmenorrhea
Primary: Mean Change in Average Severity for Abdominal/Pelvic Pain — -0.45; -0.19 units on a scale
Phase 3 N=484 Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
Endometriosis
Primary: Reduction of Dysmenorrhea (DYS) at Month 3 - Proportion of Responders — 44.0; 72.9; 23.5 Percentage of responders — p=<0.001